TaiGen Biopharmaceuticals Holdings Limited (TPEX:4157)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
10.55
-0.35 (-3.21%)
Apr 17, 2026, 1:30 PM CST
Market Cap7.51B -6.2%
Revenue (ttm)259.47M +72.2%
Net Income45.18M
EPS0.06
Shares Out711.83M
PE Ratio175.83
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,209,697
Average Volume1,300,940
Open11.00
Previous Close10.90
Day's Range10.50 - 11.00
52-Week Range7.44 - 16.40
Beta0.35
RSI37.56
Earnings DateMay 13, 2026

About TPEX:4157

TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. Its product pipeline comprises Taigexyn, which is in phase II clinical trial for the treatment of community-acquired pneumonia/diabetic foot infection; TG-1000, which is in phase III clinical trial to treat influenza A and B, and avian influenza H7N9; Furaprevir, a HCV protease inhibit... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Country Cayman Islands
Stock Exchange Taipei Exchange
Ticker Symbol 4157
Full Company Profile

Financial Performance

Financial Statements